News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Corbus to host Sept 14 call to disclose topline CANYON-1 data for CRB-913 in obesity.
  • Cellectis will hold a Sept 14 webcast to provide a business update on its allogeneic CAR-T and gene therapy programs.
  • CEA Industries reported Q1 net loss of $11.4 million, driven by a $15.3 million unrealized loss on BNB tokens.
  • Biodexa posted a £1.84 million loss for H1 and flagged material uncertainty around future financing.
  • Impact BioMedical announced a 1-for-12.62 reverse split effective Sept 23 ahead of a planned merger with Zoar Ltd.
  • Star Bulk priced a €24.50 share offering with demand over six times allotment, indicating strong investor interest.

Latest Articles

Magnite Shares Jump After Strong Q2; Management Lifts Full-Year Targets

Magnite Shares Jump After Strong Q2; Management Lifts Full-Year Targets

Magnite shares climbed sharply in pre-market trading after the company reported Q2 2026 results that beat estimates on several key metrics, led by strong contribution ex-TAC growth and margin improvement. Management raised full-year guidance and analysts responded with higher price targets, driving a near double-digit pre-open move that appears com…

Lamar Advertising Shares Rise After Q2 Beat and Upgraded 2026 AFFO Outlook

Lamar Advertising Shares Rise After Q2 Beat and Upgraded 2026 AFFO Outlook

Lamar Advertising Company shares ticked higher in pre-open trading after the company posted second-quarter results that topped expectations and raised its full-year 2026 diluted adjusted funds from operations (AFFO) per share guidance. Revenue, adjusted EBITDA, AFFO and free cash flow all increased year-over-year, providing investors with tangible …

Yardeni Says Fed Should Shift Toward a More Hawkish Stance as Inflation Risks Rise

Yardeni Says Fed Should Shift Toward a More Hawkish Stance as Inflation Risks Rise

Yardeni Research on Thursday argued the U.S. economy is on firm footing and that Federal Reserve officials ought to adopt a more hawkish policy stance. The note highlights booming consumer spending and business investment, rising GDP deflators, and an AI-driven surge in hyperscaler capital expenditures as reasons upside inflation risks now outweigh…

Tripadvisor Shares Drop Sharply After Q2 Revenue and EPS Fall Short

Tripadvisor Shares Drop Sharply After Q2 Revenue and EPS Fall Short

Tripadvisor shares tumbled in pre-market trading after second-quarter results missed Wall Street estimates on both revenue and adjusted earnings per share. A sizable revenue shortfall, coupled with a weak analyst consensus and an uneven market backdrop, weighed on the stock, which traded well below its 52-week high but above its low.

Cronos Shares Jump After Quarterly Results Exceed Expectations

Cronos Shares Jump After Quarterly Results Exceed Expectations

Cronos Group's stock climbed sharply in pre-market trading after the company posted second-quarter 2026 results that far surpassed analyst forecasts. The firm reported EPS of $0.09 versus a $0.01 consensus and revenue of $53 million, outstripping the $44.73 million estimate. The report also included multiple record performance metrics across geogra…

Fox Corp. Tops Q4 Revenue and Earnings Estimates as World Cup Ads Lift Sales

Fox Corp. Tops Q4 Revenue and Earnings Estimates as World Cup Ads Lift Sales

Aug 6 - Fox Corp. reported fourth-quarter revenue and adjusted earnings per share above Wall Street estimates, driven largely by a surge in advertising linked to its broadcast of the FIFA Men’s World Cup and continued digital expansion at its ad-supported streaming service Tubi. The company also reiterated a strategic move into connected-TV streami…

AIB Data Centers to Present Recent Financial, Power, and AI Infrastructure Milestones at the Emerging Growth Conference

AIB Data Centers to Present Recent Financial, Power, and AI Infrastructure Milestones at the Emerging Growth Conference

AIB Data Centers Inc., a U.S.-based developer and operator of AI-focused data centers, announced its participation in the Emerging Growth Conference 95 on August 19, 2026. The company will present its strong second quarter 2026 financial results, recent rebranding, successful $63 million public offering, NYSE American listing, inclusion in the Russ…

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Propanc Biopharma announced highly encouraging preclinical data for its lead candidate PRP in treating pancreatic ductal adenocarcinoma, showing over 90% tumor growth inhibition, reduced metastasis, and more than 2.5-fold increase in median survival in animal models. The data supports PRP’s novel mechanism targeting cancer stem cells and tumor micr…

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Vistagen announced positive topline results from its Phase 2 repeat dose study evaluating fasedienol nasal spray for acute treatment of social anxiety disorder (SAD). The study showed favorable safety and tolerability, with numerical improvements over placebo on primary and secondary efficacy endpoints, particularly in patients with very severe SAD…

The Metals Company Announces Second Quarter 2026 Corporate Update Conference Call for Thursday, August 13, 2026

The Metals Company Announces Second Quarter 2026 Corporate Update Conference Call for Thursday, August 13, 2026

The Metals Company Inc. announced it will host a conference call on August 13, 2026, to discuss its second quarter 2026 financial results and recent corporate developments. The company is involved in developing critical metals from seafloor polymetallic nodules, focusing on supplying metals with lower environmental impact and advancing recycling ef…

Arteris Appoints Saurabh Sinha as Chief Financial Officer

Arteris Appoints Saurabh Sinha as Chief Financial Officer

Arteris, a semiconductor technology company specialized in network-on-chip interconnect IP, has appointed Saurabh Sinha as its new Chief Financial Officer effective September 8, 2026. Sinha replaces Nick Hawkins, who is retiring after seven years and will assist with the transition in an advisory capacity. Sinha brings extensive financial leadershi…

Stran & Company Schedules Second Quarter 2026 Financial Results and  Business Update Conference Call

Stran & Company Schedules Second Quarter 2026 Financial Results and Business Update Conference Call

Stran & Company, a leading outsourced marketing solutions provider specializing in promotional products and loyalty incentive programs, announced a conference call on August 12, 2026, to discuss its second quarter 2026 financial results and corporate developments. The call will feature insights into the company’s business progress and strategic ini…

iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

iSpecimen Inc., a Nasdaq-listed online marketplace connecting scientists with biospecimens for medical research, announced the pricing of a $5 million public offering of common stock and pre-funded warrants at $1.30 per share. Proceeds will be used to repay liabilities, possibly acquire assets, invest in business and marketing activities, and for w…

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

RenovoRx announced the first commercial clinical use of its FDA-cleared drug-delivery device, RenovoCath, for treating a sarcoma patient, marking a significant expansion of the device's application beyond pancreatic cancer to other solid tumors. Treatment at CARTI Cancer Center involves localized chemotherapy delivery near the tumor, potentially re…